AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha says as Glenmark ...

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

The global modified release formulations market is set for continued expansion between 2025 and 2035, with its size projected to rise from USD 282.1 billion to approximately USD 524.7 billion, ...

AbbVie presented a user case study on the collaboration at Emerson Exchange 2025, held May 19-22 in San Antonio, Texas, showing how the implementation of wireless, real-time steam trap monitoring ...

AbbVie, a global biopharmaceutical major, announced its entry into the Indian oncology market with the introduction of Venetoclax for the treatment of both acute myeloid leukaemia (AML) and chronic ...

AbbVie Inc . (NYSE: ABBV), a leading biopharmaceutical company with a market capitalization of $375 billion, has been navigating a complex landscape of challenges and opportunities as it transitions ...